NEW YORK--()--Biotechnology company MabCure, Inc. (OTCBB: MBCI) today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure’s tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women. The patent application covers a panel of MAbs, each of which is capable of diagnosing ovarian cancer, and several that can correctly distinguish between ovarian cancer and benign tumors.
“Beyond the value of our test to diagnose ovarian cancer in a highly accurate manner and with no false positives, the potential value of our proprietary MAbs is also in helping to identify tumor-specific antigens or cancer-specific targets for the ultimate treatment of ovarian cancer”
“Filing the patent on these important discoveries is a significant step towards securing our intellectual property position and moving forward with potential strategic relationships and commercialization of what would be a highly specific serum diagnostic test for ovarian cancer,” said Amnon Gonenne, Ph.D., CEO of MabCure.
In a blinded study of 54 blood samples, MabCure’s MAbs correctly diagnosed 16 of the 17 ovarian cancers with a diagnostic sensitivity of 94 percent and 100 percent specificity. The samples were comprised of 17 patients with ovarian cancer, 5 patients with benign tumors of the ovaries, 24 healthy young females and 8 males.
“Beyond the value of our test to diagnose ovarian cancer in a highly accurate manner and with no false positives, the potential value of our proprietary MAbs is also in helping to identify tumor-specific antigens or cancer-specific targets for the ultimate treatment of ovarian cancer,” said Gonenne.
About Ovarian Cancer
Each year, 230,000 women worldwide are diagnosed with ovarian cancer, or cancer that forms in the tissues of the ovary, accounting for three percent of cancers in women. More than 125,000 women die from ovarian cancer annually, making it the fifth leading cause of cancer death in women and the deadliest of all gynecological cancers.
About MabCure’s Technology
MabCure has re-engineered classic hybridoma technology. Classic hybridoma technology is based on the generation of immortal hybrid cells or hybridoma, which follows the fusion of antibody-producing B-cells with myeloma tumor cells. Each hybridoma continuously manufactures a single monoclonal antibody. MabCure’s enhanced technology has improved upon this process by increasing MAb yield, improving production times exponentially, and enhancing specificity.
MabCure has successfully generated hybridoma libraries for four different cancers that produce, respectively, antibodies to melanoma, to an aggressive form of prostate cancer, to ovarian cancer, and to colon carcinomas. These antibodies have been shown to be specific and "universal" to each cancer, respectively, (i.e. they recognize every cancer from different individuals having that particular disease and do not react with any normal antigen tested so far). These MAbs are the first candidates for the development of novel diagnostic tools, imaging agents and drugs to treat the corresponding cancers.
MabCure is a U.S. biotechnology company whose mission is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which the company plans to develop as diagnostic tools, imaging agents and therapeutic drugs to treat lethal cancers. The company’s initial focus is on the development of novel diagnostic tests for the early detection of ovarian, prostate, and colorectal cancers, each with multi-billion dollar global market potential. MabCure is also currently exploring the potential of its anti-melanoma antibodies for the development of imaging and therapeutic agents. The company is headquartered in Hasselt, Belgium. For more information about MabCure and to sign up for e-mail updates, visit www.mabcure.com.
This news release contains “forward-looking statements.” Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company and the inability of the Company to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.